AnaptysBio Inc ANAB:NASDAQ

Last Price$30.20NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$30.20 (2)
Ask (Size)$30.22 (23)
Day Low / HighN/A - N/A
Volume172.8 K

View Biotechnology IndustryPeer Comparison as of 12/03/2021


AnaptysBio Inc ( NASDAQ )

Price: $30.20
Change: -1.47 (4.64%)
Volume: 172.8 K
4:00PM ET 12/03/2021

Kura Oncology Inc ( NASDAQ )

Price: $12.39
Change: -1.13 (8.36%)
Volume: 922.0 K
4:00PM ET 12/03/2021

Meridian Bioscience Inc ( NASDAQ )

Price: $19.60
Change: -0.16 (0.81%)
Volume: 415.7 K
4:00PM ET 12/03/2021

Chinook Therapeutics Inc ( NASDAQ )

Price: $15.16
Change: -0.58 (3.68%)
Volume: 304.3 K
4:00PM ET 12/03/2021

Syndax Pharmaceuticals Inc ( NASDAQ )

Price: $16.10
Change: -0.01 (0.06%)
Volume: 459.1 K
4:00PM ET 12/03/2021

Read more news Recent News

--Wedbush Adjusts Price Target for AnaptysBio to $35 From $32, Maintains Neutral Rating
2:40PM ET 11/05/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Insider Sell: Anaptysbio
9:41AM ET 11/03/2021 MT Newswires

Hamza Suria, Director, President, CEO, on November 01, 2021, sold 36,646 shares in Anaptysbio (ANAB) for $1,184,106. Following the Form 4 filing with the...

--Wedbush Lifts AnaptysBio's Price Target to $32 From $25 on Dostarlimab Royalty Agreement; Neutral Rating Kept
6:47AM ET 10/26/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

AnaptysBio Agrees With Sagard Healthcare to Monetize Portion of Jemperli Royalties
5:13PM ET 10/25/2021 MT Newswires

AnaptysBio (ANAB) said late Monday that it signed an agreement with Sagard Healthcare Royalty Partners to monetize a portion of AnaptysBio's future...

View all Commentary and Analysis

Wall Street Breakfast: What Moved Markets
7:42AM ET 3/13/2021 Seeking Alpha

AnaptysBio: Upcoming Catalyst Seems Like Quite The Gamble
5:20PM ET 3/02/2021 Seeking Alpha

AnaptysBio: Troubled History Of Drug Development
12:59PM ET 2/11/2021 Seeking Alpha

Company Profile

Business DescriptionAnaptysBio, Inc. is a clinical stage biotechnology company, which engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA. View company web site for more details
Address10770 Wateridge Circle
San Diego, California 92121-5801
Number of Employees78
Recent SEC Filing12/01/20218-K
President, Chief Executive Officer & DirectorHamza Suria
Chief Operating Officer & General CounselEric J. Loumeau
Chief Financial OfficerDennis M. Mulroy
Chief Medical OfficerPaul F. Lizzul

Company Highlights

Price Open$31.72
Previous Close$31.67
52 Week Range$17.72 - 37.89
Market Capitalization$830.7 M
Shares Outstanding27.5 M
SectorHealth Technology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings111.14
Earnings per Share$0.28
Beta vs. S&P 500N/A
Revenue$5.0 M
Net Profit Margin6.87%
Return on Equity2.17%

Analyst Ratings as of 09/21/2021

Consensus RecommendationConsensus Icon
Powered by Factset